Panjang
News, ER, and FDA is key.
Great news out this morning on $NASDAQ:AKER, "Akers Biosciences Inc. has entered into a three-year national distribution agreement for its flagship product with Diagnostica Stago Inc. Under the three-year deal, Stago will distribute South Jersey-based Akers PIFA PLUSS PF4 Rapid Assay, a single-use test for Heparin-induced thrombocytopenia to its customer base of hospital laboratories across the United States." (Source: John George – Senior Reporter, Philadelphia Business Journal)
This news caused the morning spike hitting a HOD of $0.9803 and closing strong at $0.92 (+15.43%) completely jumping over that trend line . With FDA still around the corner regarding their PIFA Chlamydia™ and ER expected to release on Thursday 3/29/18, we should see a very good future ahead! Next resistance may be around $1.08 but with great ER it should be able to break that, with FDA we'll be flying past $1.50 in my opinion.
Recommendation: Buy/Hold
This news caused the morning spike hitting a HOD of $0.9803 and closing strong at $0.92 (+15.43%) completely jumping over that trend line . With FDA still around the corner regarding their PIFA Chlamydia™ and ER expected to release on Thursday 3/29/18, we should see a very good future ahead! Next resistance may be around $1.08 but with great ER it should be able to break that, with FDA we'll be flying past $1.50 in my opinion.
Recommendation: Buy/Hold
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.